ConCallIQ
Go Pro
AGARWALEYE Diversified 14 Aug 2025

Dr. Agarwal's Health Care Limited — Q1 FY26

Dr.

bullish high
Compare with...
Revenue ₹487 Cr +20.8%
EBITDA
PAT ₹38 Cr +100%
EBITDA Margin
Duration 52 min
Read Time 1 min read

✓ Verified against BSE filing

Risk Intelligence

Material risks this quarter

Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.

Risks

R

Refractive surgery growth slowdown

Refractive surgeries grew only 3% YoY in Q1, attributed to seasonality and lack of promotional push. Full-year growth may not match overall surgery growth if demand does not pick up in Q2/Q3.

medium · analyst_question
R

Delhi NCR expansion execution risk

The new Delhi facility faced a 6-9 month delay due to floods. While now operational, scaling up in a competitive market may take time and could impact near-term profitability.

medium · management_commentary
R

Subsidiary merger timeline uncertainty

Management provided a broad timeline of 1-1.5 years for the merger but noted it is still under evaluation. Delays could affect corporate structure and minority shareholder returns.

low · analyst_question
R

Geopolitical disruption impact

Operations in northern India were briefly impacted by the Bahalgam attack and Operation Hindu, highlighting vulnerability to regional disruptions.

low · management_commentary